AXIM signs exclusive global licensing deal with Verséa for dry eye diagnostic tests

AXIM BIOTECHNOLOGIES, INC.

Five-year License and Distribution Agreement with Verséa for global sale of AXIM's point-of-care ocular diagnostics.
Three tests included: IgE (allergy), Lactoferrin (dry eye), and MMP-9 (inflammation); IgE and Lactoferrin are FDA-cleared.
Verséa plans to launch IgE and Lactoferrin tests at 2022 AAO and Optometry conferences; MMP-9 in 18–24 months.
Verséa must meet annual minimum sales commitments; no upfront or milestone payments disclosed.
CEO Huemoeller says deal marks transition from development-stage to revenue-generating healthcare organization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.